ADC Therapeutics SA Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
ADC Therapeutics SA (ADCT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $3.17 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- ADC Therapeutics SA share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.17, a 6.73% increase year-over-year.
- ADC Therapeutics SA share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.97, a 76.56% decline year-over-year.
- ADC Therapeutics SA share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $12.67.
- ADC Therapeutics SA share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $3.20, a 65.03% decline from fiscal 2024.
- ADC Therapeutics SA share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $9.15, a 27.27% decline from fiscal 2023.
- ADC Therapeutics SA share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $12.58, a 45.94% decline from fiscal 2022.
- ADC Therapeutics SA share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $23.27.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.17 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $3.17 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $3.20 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $3.53 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $3.62 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $2.97 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $9.15 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $9.71 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $10.50 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $12.67 10-Q · filed 2024-05-06 | |||
| 2023-12-31 | $12.58 10-K · filed 2025-03-27 | |||
| 2022-12-31 | $23.27 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |